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1. Background and objective 
Inducible transgenic and knockout systems in laboratory rodents are becoming increasingly 
widespread in biomedical research. Because of the conditional nature of the phenotype, these 
systems pose major legal challenges for scientists and authorities regarding housing or 
breeding of such animal models. We describe here the legal framework in Germany, Austria, 
and Switzerland as well as the various transgenic systems and undertake a classification.  
2. General assessment of animal welfare law  
2a. Assessment of animal welfare law in Germany 
Animal experiments are procedures or treatments performed in animals for scientific purposes 
that may be associated with pain, suffering, or harm to the animals1. But “procedures” involving 
the genotype of animals are also described as animal experiments if they might be associated 
with pain, suffering, or harm to the genetically modified animals2. Likewise included under the 
heading of animal experiments are procedures and treatments that do not directly serve a 
scientific purpose but are carried out amongst other things for the propagation of organisms3. 
The mating of animals must also be considered an “animal experiment” within the meaning of 
Germany’s Animal Welfare Act (TierSchG) if this is done with the aim of breeding offspring 
(“born or hatched”4) that carry genetic modifications which could cause pain, suffering or harm. 
In such cases, this breeding is also to be regarded as an animal experiment within the meaning 
of § 7(2) TierSchG. Such an “animal experiment” through purely breeding genetically modified 
animals is considered to be completed when no further observations are to be conducted in 
the genetically modified offspring and the offspring are also not expected to feel any pain or 
suffering as a result of these genetic modifications or suffer any lasting damage5. The outcome 
of an experiment in the generation or breeding of a new, genetically modified animal line cannot 
be reliably predicted even in cases where the influence of the genetic modification can be 
estimated with a certain degree of probability with regard to the expected phenotype. So, there 
is a “scientific purpose” here within the meaning of § 7 (2) TierSchG, first sentence, but not 
within the meaning of the second sentence. Therefore, the generation of a new genetically 
modified animal line must always be treated as an animal experiment with a scientific purpose 
in accordance with §8 TierSchG.  
Established mutants with impaired phenotype in legislation. With established mutants, 
the outcome of genetic modification with regard to the phenotype is known. It can be estimated 
whether such mutants will have to endure genetically induced pain, suffering, or damage as a 
result. Also (environmental) conditions are known under which such suffering may occur. 
However, if it has emerged from careful monitoring with the aid of suitable assessment forms6 
and has been documented in a final assessment that pain, suffering, or damage can be ruled 
                                                 
1
 § 7 (2) Sentence 1 No. 1 TierSchG 
2
 § 7 Para. 2 Sentence 1, No. 3 TierSchG 
3
 § 7 Para. 2, Sentence 2, No. 1 TierSchG 
4
 § 7 Para. 2, Sentence 1, No. 2 TierSchG 
5
 § 7a Para. 5 No. 2 Animal Welfare Act 
6
 Annexes 1, 2, 3, 4 to “Dokumentation und Veröffentlichung der Belastungseinstufung für genetisch 
veränderte Versuchstiere” in June 2013 of the German Federal Institute for Risk Assessment (BfR) 
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out in animals with genetic modifications, no approval or notification is required for further 
breeding. 
Classification of mutants with impaired phenotype. By contrast, if a genetically induced 
constraint (pain, suffering or damage) cannot be ruled out, can be expected or has been 
observed in offspring, then any further breeding requires approval. Only in a case as defined 
under §8a Para. 1 TierSchG, such as tests required by law, or if there is no scientific purpose 
as referring to the meaning of §7 Para. 2 Sentence 2 TierSchG the authorities must be solely 
notified. In cases of offspring with severe existing or anticipated constraints, however, an 
application must be submitted for approval7 
2b. Assessment of animal welfare law in Switzerland  
In Switzerland, genetically modified animals can be created within existing registered 
husbandries by use of recognized methods such as breeding, pronuclear and blastocyst 
injection. It requires a general approval for the respective procedure (application form G)8. 
These recognized methods must be carried out using a standardized procedure that is as 
animal friendly as possible9. This includes a documentation of the results8. New methods may 
possibly be recognized10. Recording the impaired phenotypes of newly created transgenic 
animals is regulated in Switzerland’s Animal Welfare Act (TierSchG), in the Animal Welfare 
Ordinance (TSchVersV), and in the ordinance of the Federal Food Safety and Veterinary Office 
(FSVO) on the housing of laboratory animals, the creation of genetically modified animals, and 
on procedures in animal experiments (Animal Experiments Ordinance [TVV]). It is 
unequivocally stipulated that, in all newly created strains and lines not sufficiently 
characterized, regardless of expectations concerning phenotype, a record of impaired 
phenotypes or absence thereof must be acquired over at least three generations and 100 
animals11 before a particular new strain can be considered to be without constraints. Monitoring 
covers nest inspections and inspections during weaning12. Between these inspections the 
animals must be observed once a week, which can be combined with the visual inspection of 
all animals13 that is conducted three times a week. The first inspection of new-borns must be 
carried out within five days of birth. The parameters of these checks on phenotypes are 
precisely defined14. As part of the procedure to record phenotypes, data on reproductive 
success and mortality must be recorded and compared with the data from non-transgenic 
animals of the same background strain. If a similar constraint is observed in several animals 
of one line, this must be reported to the competent authority (cantonal veterinary office) within 
two weeks, using application form M on a provisional basis, as stipulated in Art. 14 TVV15 and 
the authority notified of planned measures to mitigate the impairments. A definitive report is 
submitted either when the impairment is proven or at the latest after 100 animals and three 
generations16. The non-confirmation of a provisionally reported phenotype must also be 
                                                 
7
 TierSchG §8a Para. 2 No. 2 
8
 TSchG Art. 11, TVV Art. 142, TVV Annex 1 
9
 TVV Art. 9 Paragraph 3 and 4 
10
 TVV Art. 9 Paragraph 2 
11
 TVV Art. 124, TVV Art. 14 Paragraphs 3 and 4 
12
 TVV Art. 14 Para. 2 and 15 Para. 2, Art. 14 Para. 1 and 15 Para. 2 
13
 TVV Art. 2 Para. 3 
14
 TVV Annex 4 
15
 TVV, Art. 126 and 145 Para. 1 a TSchV 
16
 Art. 126 and 145 Para. 1 a TSchV, TVV Art. 18 
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reported. The breeding of lines with constraint is only possible on the scale required for the 
planned experiments. If the degree of impairment is substantial, it is necessary to weigh the 
benefits against the potential harm and undertake measures to mitigate the impairment17. The 
decision on whether to approve further breeding and supporting measures is taken by the 
cantonal authorities18. 
2c. Assessment of the legal protection of laboratory animals in Austria 
According to § 2 Subpara. 1 c) of the Austrian Animal Welfare Act (Bundesgesetz über 
Versuche an lebenden Tieren, Tierversuchsgesetz, TVG 2012) any use of animals for scientific 
purposes which is intended to or may result in a genetically modified animal line being created 
and maintained in a condition that could cause pain, suffering, anxiety or lasting damage is an 
animal experiment. Therefore, the production of genetically modified animals, regardless of 
the method or strategy used, constitutes an animal experiment and requires approval by the 
competent authority. The same applies to the breeding and housing of genetically modified 
animal lines: since the impact of a mutation on phenotype, regardless of whether this mutation 
is constitutive or conditional, cannot be reliably predicted and possible constraints of the animal 
cannot be ruled out, the breeding and housing of any new line requires approval. Projects in 
the framework of which the line is used must include a phenotype assessment of the line with 
regard to severity. The requirement to obtain approval no longer applies as soon as the line is 
established, and the presence of a largely unimpaired phenotype is proven through relevant 
documentation. As regards the criteria for the phenotype assessment, reference is made to 
the annex of the “Working document on genetically altered animals”19. It must be borne in mind 
that in all other respects (housing conditions, etc.) the breeding and housing of unimpaired, 
genetically modified animals remain subject to the legal provisions on the protection of 
laboratory animals (TVG 2012, Ordinance on Animal Experiments, TVV 2012). 
For new lines, including also multiple mutants created through breeding, a detailed 
assessment of the expected phenotype must be enclosed with the application, on the basis of 
which the severity is estimated. For lines already established, results of phenotype 
characterization are recognized from scientific publications. Insufficiently characterized lines 
are treated similar to newly created lines. 
For the approval of animal experiments in Austria and hence also for the production of 
genetically modified animals and the breeding and housing of impaired lines, a project 
assessment must be carried out according to § 29 Para. 2 TVG 2012, including a harm-benefit 
analysis. 
3. Inducible transgene expression  
Transgenic laboratory rodents play a prominent role in biomedical research. Syngeneic or 
xenogeneic transgenes are expressed in these animals. Genetically modified animal models 
are used for specific research in which influence may be exerted experimentally on the timing 
and the tissue for transgene expression or for the activity of the gene product. In principle, a 
distinction is drawn between three strategies for regulating transgene expression: (i) the 
                                                 
17
 TSchV Art.125, TVV Art. 18d and e 
18
 TSchV Art. 127 
19
 http://ec.europa.eu/environment/chemicals/lab_animals/pdf/corrigendum.pdf 
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transactivation of transcription via controllable transcription factors, (ii) sequence-specific DNA 
recombination, which involves genomic modifications and (iii) post-translational control of the 
function of a gene product. Some frequently used methods are briefly presented below. 
Expression is directly controlled either by the activation of promotors with the aid of 
endogenous transcription factors or by using an expression system that can be artificially 
activated, for which transcription factors are likewise used in transgene expression. Examples 
of promotors that can be regulated by endogenous transcription factors by means of a signal 
are Mx1 promoter by type 1 interferon (Kühn et al. 1995) or poly(I)/poly(C), 
phosphorenolpyruvate carboxykinase (Pck1) gene promoter (McGrane et al. 1988) by the 
protein and carbohydrate content of food and Hspa1b (Hsb70b) promoter by heat (Smith et al. 
2002). Other systems are based on the transgene expression of controllable transcription 
factors. Possibly the most frequently used system is the Tet-Off or Tet-On system. In this 
system, the controllability of the target transgene is achieved by transgene expression of the 
tetracycline-controlled transactivator tTA (Tet-Off system) (Gossen & Bujard 1992) or of the 
reverse tetracycline-controlled transactivator rtTA (Tet-On system) (Gossen et al. 1995) (Fig. 
1A and B). These transactivators can be placed under control of a tissue or cell-specific 
promoter. In the Tet-Off system the target transgene, which carries the tetracycline response 
element (TRE) promoter, is switched on by removing the tetracycline, usually doxycycline. In 
the case of the Tet-On system, this happens by adding doxycycline. Another system is the 
LightOn model (Wang et al. 2012) in which gene expression is induced by exposure to blue 
light (Fig. 1C). For this the transcription factor GVAP is expressed, which is dimerized under 
light and binds to the artificial promoter (Wang et al. 2012). 
However, gene expression can also be regulated by a recombinase, such as Cre, Dre or FLP 
recombinase, and their target sequences loxP, rox, and frt (Golic & Lindquist 1989; Sauer & 
Henderson 1989; Anastassiadis et al. 2009). A stop cassette consisting of transcriptional and 
translational stop mechanisms is flanked with loxP sites and located between promoter and 
open reading frame. Recombination deletes the cassette, and expression can take place (Fig. 
1D). Another possibility for transgene activation consists in bringing a DNA segment flanked 
with reverse loxP sites into transcriptional orientation through recombination mediated by Cre 
recombinase (Fig. 1E). 
4. Inducible conditional mutation of endogenous loci 
Conditional knockout systems have found widespread use in the last few years, because they 
permit a target gene to be inactivated in a particular cell type, tissue or organ of the body or at 
a set time. It is possible to determine the function of a gene more accurately with these systems 
than with constitutive knockouts. What conditional knockout have in common is that sequence-
specific recombinase systems are used to inactivate the target gene. The most frequently used 
is Cre recombinase, followed by Dre recombinase and FLP recombinase, with the 
corresponding target sequences loxP, rox and FRT. The target gene or essential parts of it are 
flanked by gene targeting, e.g. by loxP sites (“floxed”). The transgenic expression of Cre 
recombinase acts as the second part of the system. When crossed this leads to the floxed  
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Figure 1: In the Tet-Off system (A) the TRE (tetracycline response element) promoter of the transgene 
to be regulated is activated by the removal of doxycycline. In the Tet-On system (B) the TRE promoter 
is switched on by the addition of doxycycline. (C) Dimerization of GVAP by irradiation leads to activation 
of the UASG promoter element. (D) Cre-mediated deletion of a stop cassette can be used for the 
controlled activation of a gene. (E) Cre-mediated inversion can switch transgenes on and off, as 
indicated by the orientation of the word “transgene”. (F) CreERT2 can enter the cell nucleus and trigger 
recombination there only after the binding of tamoxifen. (G) Transgenic expression of a diphtheria toxin 
receptor (DTR) allows cells to be ablated by the addition of diphtheria toxin. (H) Channel rhodopsin 
(ChR) is a light-controlled cation channel. 
target region being cut out (Fig. 1D) (when the orientation of the loxP sites is identical). The 
other recombination systems are used in an analogous way. To inactivate a gene at a given 
time, the fusion protein of Cre is usually used today as a fusion with a mutated ligand-binding 
domain of the human oestrogen receptor (CreERT2) (Feil et al. 1996; Indra et al. 1999). 
CreERT2 is usually kept in the cytoplasm, bound to heat shock protein (HSP), and, after 
tamoxifen-induced dislocation of HSP, translocates to the nucleus. Here the recombination of 
the target gene takes place (Fig. 1F). A further variant of inducible Cre activity can be achieved 
through the Tet-On system by inducing the expression of Cre recombinase under control of 
the TRE element (Saam & Gordon 1999). 
A combination of the systems induces the expression of mutated exons. Here an exon or a 
gene region is flanked by loxP sites and the same region, albeit with e.g., point mutations, 
introduced behind the loxP-flanked region. Now, through Cre activity, it is possible to switch 
from expression of the wild-type protein to the mutated protein in the endogenous locus (Kraus 
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5. Viral and further gene expression systems  
The introduction of DNA or RNA into somatic cells by viruses, chemical or physical methods 
also represents a form of induced transgenic gene expression in the widest sense of the term. 
Retroviral and lentiviral expression is often used to modify cells of the haematopoietic system 
and is stable as a result of integration into the genome of the target cells. In this way the entire 
immune system of modified cells can be built up through the transduction of haematopoietic 
stem cells following the generation of bone marrow chimeras (Szymczak et al. 2004). 
Adenovirus can be used for the liver, albeit with expression that is only transient as a rule. In 
the neurosciences, adeno-associated virus (AAV) (Smith et al. 1995) and rhabdovirus 
(Wickersham et al. 2007) are often used to introduce transgenes into cells of certain regions 
of the nervous system. A physical method of introducing a transgene is the use of 
hydrodynamic transfection of hepatic cells with a plasmid (Liu et al. 1999). Also included in 
these systems is DNA vaccination by intramuscular injection. As a rule, both lead to transient 
expression. Lipofection is a form of chemical introduction of transgenes into cells and can be 
successfully used in vivo in combination with cavitation (formation and collapse of bubbles in 
liquids). 
6. Inducible activity of transgene products 
In systems of this type, the effect of the transgene is obtained not by controlling expression but 
by chemical or physical inducing factors. Since some of these systems can also be used for 
transcription control, there is a certain overlapping with the systems already described. The list 
of such models is long and highly specific for pertinent fields of research. 
Cell ablation systems allow certain cells to be killed at a defined point in time. These include 
the Herpes simplex thymidine kinase system, which leads to the death of dividing cells 
following the administration of ganciclovir (Bush et al. 1998), and also the diphtheria toxin 
receptor system (Fig. 1G), in which cells transgenically labelled with the receptor are killed by 
injection of the Diphtheria toxin (Saito et al. 2001). Using recombination in combination with 
cell ablation is effective for transcriptional activation of Diphtheria toxin A expression (Ivanova 
et al. 2005; Brockschnieder et al. 2006). Here, a stop cassette is often deleted by Cre-mediated 
recombination following the administration of tamoxifen. In optogenetic systems, the activity of 
nerve cells is regulated by light exposure. The proteins to be mentioned here are Channel 
rhodopsin (Boyden et al. 2005) and Halorhodopsin (Han & Boyden 2007), which act as cation 
and chloride channels respectively. 
7. Classification of inducible transgenic and knockout systems, as well as 
other recombination systems in animal welfare law 
7a. Inducible transgenes and German animal welfare regulations 
Back in 1996, the German Federal Ministry of Research at the time drew up an information 
paper on the classifying the production of genetically modified animals under animal welfare 
legislation. The core statements of this paper (Cramer et al. 1996), which broadly still apply 
today, are: 
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a) According to the German Animal Welfare Act (TierSchG), the creation of transgenic or 
knockout animal strains constitutes an animal experiment and, if the animals in 
question are vertebrates or (since 2013) cephalopods, is subject to approval by the 
authorities. 
b) The further breeding of such genetically modified animals beyond the second 
generation did not have to be either reported to or approved by the authorities until the 
amendment of TierSchG in 2013 but was considered simply a breeding activity as 
defined in §11 TierSchG. Also, the further breeding of animals that are carriers of 
genetic modifications with harmful effects on health was and still is permitted, provided 
this serves a scientific purpose20. Animal breeders are still required to take every action 
to ensure the wellbeing of the animals under the housing conditions necessary for 
them. A prerequisite for exercising this duty of care is that all the personnel involved in 
the care of the animal stock possess adequate expertise21, especially with regard to 
the nature and function of specific mutations of the animals. The duty of care also 
implies adequate veterinary monitoring of the animal stock and, where applicable, any 
treatments required together with adequate documentation of the measures carried 
out. As a result of the change in animal welfare law demanded by the European Union 
in 201022 it is necessary also to notify the competent authorities or request approval for 
the further breeding of genetically modified animals if observations / investigations on 
their characterization are conducted in the offspring or pain, suffering or damage is 
expected to be found as a result of the genetic modification. 
Aside from these considerations, of course, any experiments in genetically modified animals 
that could lead to pain, suffering or damage must still be notified to the authorities or approval 
obtained from the authorities depending on the purpose of the research and the stress on the 
animals. 
The listed key points of the information paper produced by the former German federal ministry 
of food, agriculture and consumer protection also apply of course to inducible transgenic or 
knockout animals. The induction measures are assessed under animal welfare law on the 
basis of the following factors: 
a) Purpose of induction: Induction may be performed for a scientific purpose. Induction 
may, however, also constitute a veterinary treatment of breeders of particular strains 
or may serve the purpose of preserving a strain of animals. It can thus be considered 
part of the responsible person’s duty of care according to § 11 TierSchG. For example, 
the Tet-Off system is active without any intervention, but it can be prevented from 
activation or can be switched off by adding doxycycline as an inductor (see Fig.1). In 
breeders and in stock animals containing the Tet-Off system, administration of 
doxycycline can thus be used to prevent the expression of a gene product that is 
harmful to their health. In this case, the administration of doxycycline is compulsory and 
approval or notification is only required if the harmful effect of the gene product cannot 
be completely prevented by this means or if pain, damage or suffering is triggered in 
                                                 
20
 § 11b Para.3 TierSchG 
21
 § 3, Para.1, No. 1 and §11 ara.1, No.1 and 2 TierSchVersV, Wilson et al., 1995; Nevalainen et al., 2000; 
Nevalainen et al., 1999 
22
 EU Directive 2010/63EU, amendement of TierSchG and TierSchVersV 
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the animals by the doxycycline or the administration procedure itself (injections or the 
like). 
However, there are interpretative approaches that regard such measures as a 
“refinement”, because while they minimize the risk of stress, they do not completely 
eliminate it. Therefore, they are seen as a reason always to classify any such 
procedure, e.g. administration of doxycycline in the Tet-Off system, as an animal 
experiment according to the EU Directive23. But in concrete terms, the Directive23 states 
that the “elimination of pain, suffering, distress or lasting harm by the successful use of 
anaesthesia, analgesia or other methods” is no reason for not including the animals 
concerned within the scope of the Directive, in other words for not regarding them as 
animals in an animal experiment. However, it is only possible to eliminate or switch off 
something that exists or is switched on. So, what is meant is a situation in which a 
noxious agent already exists as a potential cause of pain, fear, suffering or lasting 
damage and the stress resulting from this is eliminated using appropriate measures. In 
the case of appropriate doxycycline administration (induction) in mutants using the Tet-
Off system, the expression of a harmful gene product is almost certainly prevented until 
the treatment is discontinued. Consideration of a possible “residual risk” that an 
impairment may occur is not addressed in the EU Directive, so it has to be assumed 
that this norm only refers to specific noxious agents already active and actually present 
in the animal, but not to the hypothetical possibility that a constraint could occur as a 
result of special circumstances. 
b) Impaired wellbeing of animals as a result of the induction per se: It must be established 
whether the induction, i.e. the administration of e.g. doxycycline (Tet-On) or tamoxifen 
(CreERT2) per se causes pain, suffering or damage. If the inductors are administered 
by the parenteral route, it must generally be assumed that an impairment is caused by 
the induction itself (injection pain). But the administration of inductors via the food or 
the drinking water may also be classified as stressful if it leads to the food intake being 
temporarily or permanently impaired. 
c) Impaired animal wellbeing as consequences of induction: it must be established 
whether the induction of a transgenic or knockout system can lead to pain, suffering or 
damage in the animals concerned. When it comes to inducible transgenic systems, it 
can be assumed this is so in cases where the target gene product has pathogenic 
properties. But it can also be caused by harmful effects resulting from the 
overexpression of a physiological gene product. For example, the liver-specific 
overexpression of the pro-inflammatory cytokine IFN-γ leads to hepatitis (Toyonaga et 
al., 1994). On the other hand, the induction of a tissue-specific knockout defect does 
not necessarily bring with it a constraint for the carrier animals. 
d) Performance of other procedures: as summarized in Table 1, the induction of a 
transgenic or knockout system for scientific purposes through the administration of an 
inductor must always be reported to or approved by the authority if the induction itself 
or the consequences thereof may result in stress for the animals (pain, suffering or 
damage) or if further stressful procedures are carried out. A requirement to report or 
obtain approval for the induction is only inapplicable in cases where stresses are 
caused neither by the induction itself nor by its consequences and where no further 
procedures are carried out. 
                                                 
23
 EU Directive 2010/63/EU Art. 1 (2) 3rd sentence 
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The holders of animal housing permits according to §11 TierSchG are required to minimize the 
harmful impacts of mutations in breed animals and stock animals. This duty of care also 
extends to inducible transgenic and knockout systems. For example, crossings for combining 
the required transgenes and alleles of an inducible system are to be kept to the absolute 
minimum necessary if there is any fear of health impairments in the offspring. If there is a 
possibility of system-specific constraints occurring in breed and stock animals of inducible 
transgenic and knockout systems, an adequate health monitoring system must be installed 
and clear criteria defined for the humane killing of impaired animals (criteria for 
discontinuation). If in the case of inducible transgenic and knockout systems the inductor (e.g. 
doxycycline with the Tet-Off system for shutting down gene expression) is administered as part 
of the duty of care (on the part of the housing permit holder as defined in §11 TierSchG), this 
is not subject to any requirement to report or obtain approval for the procedure if this 
(veterinary) treatment itself does not cause pain that is more severe than or as severe as the 
pain of an injection using a cannula. Such a minimal level of stress can be tolerated for 
administering with the drinking water or food if this is well accepted and ingested voluntarily. 
These (veterinary) measures will predominantly affect the Tet-Off system, in which the 
transgenic system remains in a state of shut-down as a result of doxycycline administration. In 
this way, the expression of harmful transgenic products, such as those of oncogenes, can be 
inhibited in breed or stock animals. Cases are also possible, however, in which an 
improvement can be achieved in the health of carrier animals by activating a Tet-On system. 
Such a case occurs, for example, in defect mutants when the specific defect can be 
compensated by the activation of a Tet-On system. The keepers of such genetically modified 
animals, which can only live free of pain or suffering with appropriate medication, are required 
to guarantee the animals receive the necessary treatment as demanded. If they want to omit 
treatment for scientific reasons, they must always obtain approval for the animal experiment 
respectively notify the competent authority. 
According to the new animal welfare legislation, however, the breeding itself is also deemed 
to be an animal experiment which must be reported or for which approval must be obtained if 
the genetically modified animals are impaired in their wellbeing despite therapeutic or palliative 
measures or because there is no knowledge of such measures being administered. 
As with all animal experiments, so too with breeding (targeted reproduction of organisms), the 
purpose and other conditions are pivotal in deciding whether this animal experiment requires 
approval by or notification of the authority. Animal experiments that require approval are those 
which serve a scientific purpose and whose result is not sufficiently known, even if the objective 
is to conduct a duplicate or repeat experiment for a mandatory review of an experimental result 
that is sufficiently known24. Instead of the requirement for approval, however, there is under 
certain circumstances a duty to notify the authority, e.g. when such experiments are required 
by law25. Notification (20 working days before the start of the experiment; for start of the 
experiment see Confirmation of receipt26) is sufficient also, for example, if the animal 
experiment is conducted according to proven methods and e.g. for the reproduction of 
organisms27. 
                                                 
24
 § 8 Para. 1, No. 1 TierSchG 
25
 § 8a Para. 1, No. 1 TierSchG 
26
 § 36 TierSchVersV 
27
 § 8a Para. 1, No. 3 a TierSchG 
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However, if phenotypes resulting from genetic modification or from a necessary treatment 
method are to be classified as “severe”28, an application for the approval of any such breeding 
must always be obtained before the start of mating. Mating may only be started after approval 
has been obtained. In the event of considerable pain or suffering that is prolonged and cannot 
be alleviated, however, the approval may be revoked by the EU Commission29. 
7b. Inducible transgenes and Swiss animal welfare regulations 
Swiss legislation requires a record of impairments for all newly produced or newly imported 
genetically modified lines. On the basis of this record, a decision is made as to whether a line 
is without constraint and can continue to be bred without a special permit or may only be 
housed after approval by the cantonal authorities (see Section 1b). The production of 
genetically modified animals is not an animal experiment requiring an individual application for 
approval but may be carried out after a simplified approval procedure (application using Form 
G). In the case of a newly created line, the initial characterization, i.e. also the killing of animals 
for the analysis of organs or cells, may proceed without a specific approval for animal 
experimentation. In the case of established lines, however, the killing of animals for the 
analysis of organs or cells requires approval. The administration of inductors or repressors of 
transgene expression, such as with the Tet system, may be considered a constraint-mitigating 
measure after consultation with the cantonal authority. The authority may, however, also 
require this line to be reported as impaired using Form M. Then the authority will decide on 
breeding restrictions. With respect to the application for approval of an animal experiment the 
suffering as the result of a gene-specific phenotype has to be considered together with that of 
a planned experiment, both, in the prospective classification of the constraint and when 
weighing the benefits against the harm. 
7c. Inducible transgenes and Austrian animal welfare regulations 
Classification of the severity of the prospective impairment of genetically modified animal lines 
requires in principle the assessment of each individual case, which must also take into account 
the different conditional alleles of a gene or the specific activation conditions of an inducible 
system where applicable. A phenotype assessment is thus also undertaken for lines with 
conditionally inducible mutations whose genetic modification alone is not expected to influence 
the phenotype. 
If the conditional trait of a transgenic locus rests on the use of recombinases or integrases, this 
usually requires the breeding of a duplicate mutant, resulting in a new line to be assessed. If 
the activation of the conditional mutation involves the administration of inductors by means of 
a method that can cause pain, suffering, fear or lasting damage, approval is generally required 
for this within the framework of a separate research project. The enteral administration of 
specific medicines as activator or repressor in the drinking water or the food is not subject to 
any requirement for approval provided it does not compromise food intake and no side effects 
are to be expected following the administration of these substances. In all other cases, the 
effect on the wellbeing of the animals and the potential level of impairment are to be assessed 
depending on the circumstances of the specific individual case (experimental design). In this 
way, for example, a decision may be reached to dispense with the evaluation of a new mutant 
                                                 
28
 § 8a Para. 2, No. 2 TierSchG 
29
 § 26 Para. 1 TierSchVersV 
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with tissue-specific inactivation if the constitutive knockout of this gene has already undergone 





Fig. 2: Flow diagram as decision-making aid to the legal classification of inducible mutants, based on 
the assumption that a permit has been obtained for the breeding and housing (§11 TierSchG) of 
(genetically modified) laboratory animals. 
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approval or notification 
without induction 
Constraint by the 
induction itself 
Requirement for approval or notification with induction 
Tet-Off 
Administration of doxycycline 
shuts down gene expression. 
Depending on transgene Depending on transgene 
Drinking water: no in the 
case of acceptance* 
In unimpaired transgenic phenotype under treatment: no* 
In impaired transgenic phenotype under treatment: yes 
Tet-On 
Administration of doxycycline 
activates gene expression. 
No No 
Drinking water: no in the 
case of acceptance 
No / in impaired transgenic phenotype: yes 
LightOn 
Induction of gene expression by 
blue light. 
No No 
Light: no, depending on 
the study 
No / in impaired transgenic phenotype: yes 
MX-Cre 
Induction of the transcription of 
Cre-recombinase by type 1 
interferon or poly-I/poly-C. 
No No i.p. injection: yes Yes 
HSP70 
Promoter 
Induction by heat, e.g. by MRI-
focused ultrasound. 
No No Heat: yes Yes 
CreERT2 
Induction of Cre activity by binding 
of tamoxifen. 
No No 





In impaired transgenic phenotype: yes 
floxed 
STOP cassette 
Deletion of a STOP cassette by a 
recombinase (Cre, Dre etc.). 
No No - In impaired transgenic phenotype: yes 
Inversion 
Inversion of a loxP-flanked gene 
segment. 
No No - In impaired transgenic / ablation phenotype: yes 
loxP, rox 
flanking 
Removal of a gene segment. No No - In impaired ablation phenotype: yes 
Diphtheria toxin 
receptor 
Cell ablation by injection of 
diphtheria toxin 
No No i.p. injection: yes Yes 
Channel 
rhodopsin 
Light-induced cation channel. No No 
Light alone: no 
With restraint / 
anaesthesia: yes 
With phototoxicity: yes 
In impaired induced phenotype: yes 
Halorhodopsin Light-induced chloride channel. No No 
Light alone: no 
With restraint / 
anaesthesia: yes 
With phototoxicity: yes 
In impaired induced phenotype: yes 
Thymidine 
kinase 
Cell ablation through 
administration of ganciclovir. 
No, occasionally male 
sterility. 
No 
Drinking water: no in the 
case of acceptance  
i.p. injection: yes 
Drinking water: no in the case of acceptance i.p. Injection: yes 
In impaired transgenic phenotype: yes 
 
Table 1: Classification of various inducible transgenic systems under animal welfare law, *Doxycycline may possibly be administered as part of the duty of care of the 
animal keeper as specified in §11 or as a breeding measure (CH) 
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Disclaimer  
Any use of GV-SOLAS publications (specialist information, statements, booklets, recommendations, 
etc.) and application of the information contained therein are at the express risk of the user. Neither GV-
SOLAS nor also the authors can accept liability for any accidents or damages of any kind arising from 
the use of a publication (e.g. resulting from the absence of safety instructions), irrespective of legal 
grounds. Liability claims against GV-SOLAS and the author for damages of a material or non-material 
nature caused by the use or non-use of the information or by the use of erroneous and/or incomplete 
information are in principle excluded. Legal claims and claims for damages are therefore excluded. The 
work, including all content, was compiled with utmost care. However, GV-SOLAS and the authors 
assume no responsibility and no liability for the currentness, correctness, completeness or quality of the 
information provided or for printing errors. GV-SOLAS and the authors accept no legal responsibility or 
liability in any form for incorrect statements and consequences arising therefrom. Responsibility for the 
content of the internet pages printed in these publications lies solely with the owner of the websites 
concerned. GV-SOLAS and the authors have no influence on the design and content of third-party 
websites and therefore distance themselves from all third-party content. Responsibility within the 
meaning of press legislation lies with the board of GV-SOLAS. 
 
 
